CDK9 and cervical carcinoma: In summary, the results of our 2D- and 3D-cellular experiments demonstrated that the response of cervical cancer to Cisplatin-based standard chemotherapy might significantly improve by concurrently blocking CDK9 activity using small-molecule inhibitors.